Tiotropium: What came after the UPLIFT study

Pierachille Santus, Fabiano Di Marco, Dejan Radovanovic, Stefano Centanni

Research output: Contribution to journalArticle

Abstract

Introduction: Chronic obstructive pulmonary disease (COPD) is characterized by a progressive bronchial obstruction, and bronchodilators represent the maintenance therapeutic choice. Tiotropium is an anticholinergic drug that is proved to be safe, efficient and simple to handle; Respimat® technology was recently introduced as a new device for tiotropium administration. Areas covered: This paper reviews clinical trials and meta-analyses, with tiotropium efficacy as a primary end point, found in MedLine, the Cochrane trials database and Embase. Only the literature published after the UPLIFT study has been considered. Expert opinion: Data published after the UPLIFT study confirms the efficacy of tiotropium as maintenance COPD therapy and its capacity to reduce airflow obstruction, as well as lung hyperinflation. Nevertheless, there is a certain inhomogeneity in the definition and evaluation of COPD exacerbations, in lung functional parameters and quality-of-life assessment, and there has not always been a proper comparison between tiotropium and other long-acting bronchodilators. Respimat is comparable in efficacy to the HandiHaler®, using bioequivalent doses of tiotropium.

Original languageEnglish
Pages (from-to)613-618
Number of pages6
JournalExpert Opinion on Pharmacotherapy
Volume13
Issue number4
DOIs
Publication statusPublished - Mar 2012

    Fingerprint

Keywords

  • Anticholinergic
  • COPD
  • Outcome
  • Respimat
  • Tiotropium

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Santus, P., Di Marco, F., Radovanovic, D., & Centanni, S. (2012). Tiotropium: What came after the UPLIFT study. Expert Opinion on Pharmacotherapy, 13(4), 613-618. https://doi.org/10.1517/14656566.2012.656592